Biologics Blossoming: CANbridge Looks To Taiwan, WuXi Partners Juno

PharmasiaNewsBiologics Blossoming: CANbridge Looks To Taiwan, WuXi Partners Juno

By Brian Yang

Apr. 11, 2016 7:05 AM GMT

https://www.pharmamedtechbi.com/Publications/Pharmasia-News/2016/4/11/Biologics-Blossoming-CANbridge-Looks-To-Taiwan-WuXi-Partners-Juno?result=1&total=22&searchquery=%253fq%253dCANbridge

Executive Summary

New policies including the allowance of contract manufacturing under a new marketing holder system are fast changing the nascent biologics sector in China, where the just 2% market penetration for such products is offering plenty of room for a new crop of startups including CANbridge to grow and thrive.

BEIJING – Many seemingly unconquerable barriers of the past are fast melting away, and biotech companies in China are wasting no time to seize new opportunities.

One such obstacle has been manufacturing site requirements. Previously in China, drug makers must have had their own production facilities to be able to conduct clinical trials for their new drugs, but now a pilot program is allowing contractor manufacturers to be used instead (“Authorization Holder Scheme To Shake Up China R&D, Production” — PharmAsia News, Nov. 6, 2015 4:18 AM GMT).

That is opening doors for smaller biotech startups like CANbridge Life Sciences Ltd. With fewer than 20 people and a virtual development model, the Beijing-based firm simply has to rely on contract manufacturing organizations (CMOs) for any chance of developing a new drug in China.

Now, the company has a concrete solution. It has signed up with WuXi Biologics, a subsidiary of WuXi AppTec Inc. to produce CAN-008 in China. The molecule, also known as APG001, was licensed by CANbridge in July 2015 from Germany’s Apogenix GMBH for mainland China, Hong Kong and Macau, and is at the clinical stage elsewhere for glioblastoma multiforme, a type of brain cancer.

The partnership with WuXi will allow CANbridge to submit a planned IND for clinical trials to the China FDA. Wasting no time, the company has meanwhile completed an IND application (the venture’s first) to initiate a Phase I/II trial in Taiwan (which is now included in its licensed territories) to help expedite the regulatory process in the mainland, disclosed James Xue, CANbridge’s CEO.

“Due to a ‘four plus four’ agreement between the mainland and Taiwan, in which clinical trial study data from four selected facilities from each side are accepted by the [respective] regulatory agencies, we hope the data obtained from the Taiwan study will be used towards starting Phase II trials in the mainland, bypassing a Phase I study [in China],” explained Xue in a phone interview. Data from the Taiwan study are expected next year, he added.

Such a development approach is a direct result of a cross-strait clinical study collaboration agreement, a pathway that several Taiwanese biotechs including Taiwan Liposome Co. Ltd. are hoping to use to get their novel drugs approved in a far larger market (“Taiwan Liposome Eyes Phase II Liver-Cancer Drug Trials At Home, China” — PharmAsia News, Aug. 11, 2014 10:33 PM GMT).

CANbridge has also recently in-licensed global rights ex-US, Canada and Mexico to AVEO Oncology‘s clinical stage ErbB3 (HER3) inhibitor for esophageal squamous cell cancer (ESCC) (“CANbridge Looks Beyond Asia With AVEO’s Oncology Drug” — PharmAsia News, Mar. 24, 2016 7:59 AM GMT).

Clinical Benefits Matter

Unlike its biotech peers, which are focusing on cancer types that are prevalent in China such as lung, liver and gastric cancer, Xue’s firm is fixing its eyes on brain tumors and esophageal squamous cell carcinoma. The executive said that although patient numbers matter, identified patients and clinical benefits carry more weight.
Eventually the individual who are new to their canada viagra online sexual life because of erectile dysfunction. Out of all the medicines prescribed for erectile dysfunction as they are very strong as well as harmful so one should not intake it by any possible chance. buy sildenafil is a product used for curing erectile dysfunction completely from men around the globe. In a way, the blood vessels easily flow into this region cialis cost & it leads for enhancement of the capability to reduce the incapability and can avail man to get over the highly pathetic factor. They always calculate their ovulation and have sex with partner on a regular basis to stay away from hot working areas and wear loose undergarments to ensure enhanced oxygen find to find out more buy generic levitra supply to keep the reproductive organs healthy.
Glioblastoma multiforme is the most prevalent and aggressive form of brain cancer, and the current standard first-line treatment is Temodar (temozolomide injection), a chemotherapy agent developed by Merck & Co. Inc. and first marketed in 1999.

The average survival in the malignancy is roughly seven months, resulting in a large unmet medical need, Xue said.

A CD95-Fc fusion protein in the TNF family, APG101 is currently under Phase II study for glioblastoma and is the first targeted therapy for the indication in late-stage development, with Apogenix planning to start a Phase III program in Europe.

Although the drug is being studied as a second-line therapy in Europe, the 55-patient Taiwan study (set to start in August) will test it in the first-line setting in combination with temozolomide, during and after radiation therapy. The data generated are also expected to complement the Apogenix data obtained in Europe, Xue said.

“A clear pathway and potential benefits to patients” provided CANbridge with the main reasons to license the asset for greater China. Additionally, Xue said the company is also looking to expand to other cancer indications once it obtains proof-of-concept data. APG101 is already being developed for myelodysplastic syndromes, where CANbridge has an option to acquire selected rights.

Similarly, there is a lack of effective treatments for ESCC, which affects people in certain regions of China.

MAH Impact

China’s rollout of the marketing authorization holder (MAH) pilot scheme is enabling smaller biotechs like CANbridge to file for their own regulatory approvals for the first time. “MAH is opening the door,” Xue pointed out, adding that WuXi is one of the few CMOs with international standards.

Another factor is that WuXi has experience filing new drug approvals with the China FDA. Even as the goal is to develop the Apogenix asset into an international first-in-class drug, Xue said manufacturing such a product will even be a new challenge for WuXi.

In another move under the MAH scheme, German’s Boehringer Ingelheim GMBH has also set up a CMO subsidiary in China and has partnered with BeiGene (Beijing) Co. Ltd. to manufacture BeiGene’s anti-PD-1 monoclonal antibody BGB-A317 (“Beigene/Boehringer Biomanufacturing Bond Tests China MAH System” — PharmAsia News, Mar. 10, 2016 6:28 AM GMT).

WuXi Links With Juno

Meanwhile, WuXi – China’s largest contract research organization – has been busy signing other deals, including wit Juno Therapeutics Inc. to set up a 50/50 joint venture, JW Biotechnology (Shanghai) Co. Ltd, to develop immune-oncology products in China.

The JV will leverage Juno’s technology in chimeric antigen receptor (CAR) and T-cell receptor drugs and WuXi’s R&D and manufacturing capabilities, and plans to in-license the rights in China to Juno products in exchange for undisclosed upfront, milestone and royalty payments.

The new joint venture is being led by WuXi’s co-founding CEO James Li, formerly a partner with Kleiner Perkins and GM for Amgen Inc. in China, while WuXi chairman Ge Li serves as chairman. Other board directors include Juno CEO Hans Bishop, Juno CFO Steve Harr and WuXi CFO Edward Hu.

Juno is one of the portfolio firms that had previously received investment from WuXi Healthcare Ventures (“WuXi AppTec Aiming To Relist Biologics Unit In Hong Kong IPO” — PharmAsia News, Mar. 4, 2016 1:21 AM GMT).

UPDATED: China’s CANbridge files Taiwan IND for PhI/II anti-TNF candidate

FiercePharmaAsiahttp://www.fiercepharmaasia.com/story/chinas-canbridge-files-taiwan-ind-phiii-anti-tnf-candidate/2016-04-07

Topics:

Clinical trials | Partnering

UPDATED: China’s CANbridge files Taiwan IND for PhI/II anti-TNF candidate

Adds comments from Xue

April 7, 2016 | By EJ Lane

Share

Beijing-based CANbridge Life Sciences has sent the Taiwan FDA an Investigational New Drug (IND) application for candidate CAN-008 aimed at brain cancer immunotherapy that was in-licensed for China rights from Germany’s Apogenix.

 CEOJamesXue

CANbridge Chairman and CEO James Xue

After this was seen; many made a good research to find out the reason for this by just making love more information order levitra to him. Risks associated with MRgFUS Although there are minimal risks within the viagra cheapest online procedure there exist some. Erectile dysfunction is not just an emotional for sale viagra problem, and with these tablets, you can lead a more confident and sexually healthy life. The medicine have very fast levitra 20mg generika action time and last up to 50% longer than other medicine available in market for same use.
The Taiwan trials will see CAN-008 administered with temozolomide (Temodar) along with radiation therapy for 55 patients in the open-label, dose-escalation Phase I on safety, tolerability pharmacokinetics and preliminary efficacy, according to a press release.

The WuXi Biologics unit of Shanghai-based WuXi AppTec will manufacture the candidate in China, aiming to use the speedier IND process in Taiwan as a possible springboard into Mainland China, though the pathway relies on China FDA granting a fast-track review.

“We are delighted to join forces with WuXi, which will manufacture CAN-008 for the Chinese market, where we plan to begin the pre-clinical work immediately, preparatory to an IND submission,” James Xue, CANbridge Chairman and CEO, said in a statement. CANbridge will rely on WuXi for CD-95 fusion protein.

In a phone interview with FiercePharmaAsia, Xue said that patient enrollment should be finished by the end of the year and results for the Phase I leg out by the second quarter of 2017. He said the trial was being conducted under a 4 + 4 arrangement between Taiwan and China that recognizes clinical trial data from 4 hospitals in each country.

In that regard, CANbridge hopes to take successful Phase I data to the China FDA for an IND application and if the data is exceptional – aim for a straight shot into Phase II without having to repeat the Phase I in China.

With a bit more than $15 million raised up to Series A, Xue expects Series B cash this year at around twice that amount to carry on work through 2018, adding that he sees the biotech space in China moving to a “self-select” mode in funding in the coming years as excellent talent and candidates are in place now.

The multi-center, double-blind, randomized, placebo-controlled Phase II leg of the trial eyes efficacy and safety with a start date seen in August of this year.

Apogenix’s own efforts in a Phase II trial in Europe saw increased median survival to 16.1 months from 6.5 months and meeting efficacy endpoints and no serious adverse effects.

In March, CANbridge inked a deal worth a potential $134 million deal with Nasdaq-listed Aveo Oncology ($AVEO) for a clinical-stage ErbB3 (HER3) antibody candidate AV203.

CANbridge received $10 million in venture capital financing in October of last year, led by Qiming Venture Partners and TF Capital, the venture arm of Chinese CRO Tigermed, which built on angel investor funding of the same amount received in 2014.

Canbridge confirms ligand CD95 in Chinese patient biomarker study

By Shannon Ellis, Staff Writer ©2016. REPRINTED WITH PERMISSION FROM THOMSON REUTERS. SHANGHAI – Canbridge Life Sciences Inc. has confi rmed the existence of ligand CD95 in Chinese glioblastoma patients after completing the fi rst such biomarker study of its kind on the mainland. There are viagra no prescription but choose always the best. Maximum extent of the individuals cheap cialis 20mg desire to consume varied types of medicines. Kamagra and other similar generic medication is cheaper than branded online tadalafil . What’s more, if men have unprotected sex with women, they also can have women infected. order viagra without prescription The study demonstrated a high degree of CD95 ligand expression consistency between geographically diverse Chinese and Western glioblastoma multiforme patients. Earlier this year, Beijing-based Canbridge licensed the China rights – including Hong Kong and Macau for APG101 (also known as CAN008), a targeted CD95 therapeutic – from Apogenix GmbH, of Heidelberg, Germany, for an undisclosed amount. (See BioWorld Asia, July 22, 2015.)

Click here to read the full article.